Online Exclusives

Online Exclusives

Third-Largest Insurance Company Set to Exit ACA Marketplace by 2018

Aetna will no longer offer individual plans in the Affordable Care Act (ACA) insurance exchanges in 2018, because of declining sales and uncertainty over...

Pembrolizumab Approved by the EU for Relapsed/Refractory Classic HL

Pembrolizumab has been approved by the European Commission for the treatment of relapsed or refractory classic Hodgkin lymphoma (cHL) in adult patients whose disease...

WHO to Bring Affordable Biosimilar Drugs to Low- and Middle-Income Countries

The World Health Organization (WHO) is slated to launch a pilot project to evaluate biosimilar agents of expensive anti-cancer drugs to make the treatments...

FDA Grants Breakthrough-Therapy Designation to CTL019 for Adult DLBCL

The U.S. Food and Drug Administration (FDA) has granted breakthrough-therapy designation to the investigational chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel-T, also known as...

Congress Increases Funding for Current NIH Fiscal Year by $2 Billion

Rejecting President Trump’s call for budget cuts, Congress voted on a bipartisan spending agreement that will increase National Institutes of Health (NIH) funding by...

Tazemetostat Gets Second Fast-Track Designation from FDA

The U.S. Food and Drug Administration (FDA) has granted fast-track designation to tazemetostat, an EZH2 inhibitor, for the treatment of patients with relapsed or...

House of Representatives Approves New Health Care Act

On May 4, the Republican-majority House of Representatives approved the American Health Care Act (AHCA) with a 217-213 vote, passing by a margin of...

Pembrolizumab Appears to Improve Survival in Ongoing Trial of Relapsed/Refractory PMBCL

Author’s Perspective Lead author Pier Luigi Zinzani, MD: “In this ongoing trial, pembrolizumab achieved a treatment response rate of 41 percent, while median duration of...

Proposed Rule Would Make Hospital Inspections More Transparent

Hospital inspection reports concerning errors and violations have long been kept confidential, but a new proposed rule by the Centers for Medicare and Medicaid...

ASH Joined Other Scientific and Health Organizations to March for Science

On April 22, 2017, 25 scientific and medical societies, including the American Society of Hematology (ASH), participated in the March for Science, drawing attention...
Advertisement

Current Issue

May 2017, Volume 3, Issue 6

This issue discusses the legacy of Agent Orange and hematologic malignancies, a debate over transplant in myelodysplastic syndromes, and more.